AP
ALXN

Archon Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Archon Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-23,100
Closed -$3.24M – 64
2017
Q3 		$3.24M Buy
+23,100
New +$3.14M 0.76% 39
2013
Q4 		– Sell
-39,500
Closed -$4.59M – 66
2013
Q3 		$4.59M Buy
+39,500
New +$4.33M 1.39% 42

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Archon Partners's ALXN Position: Q4 2017 in Review

Archon Partners sold out of Alexion Pharmaceuticals (ALXN) in Q4 2017, closing a stake of 23,100 shares — an estimated $3.24M sold.

Archon Partners first reported a position in ALXN in Q3 2013 and held it in 2 quarters. The position peaked at $4.59M in Q3 2013. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

  • Archon Partners reported no remaining Alexion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Archon Partners sold 23,100 Alexion Pharmaceuticals shares in Q4 2017, an estimated $3.24M.
  • Archon Partners first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 2 quarters.
  • Archon Partners's Alexion Pharmaceuticals position peaked at $4.59M in Q3 2013.
  • 587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on Archon Partners's 13F filing for Q4 2017, filed 5 Feb 2018.